These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30986252)

  • 1. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
    Turtle L; Brindle HE; Schluter WW; Faragher B; Rayamajhi A; Bohara R; Gurung S; Shakya G; Yoksan S; Dixit S; Rajbhandari R; Paudel B; Adhikari S; Solomon T; Griffiths MJ
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
    Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.
    Wang R; Xie L; Gao N; Fan D; Chen H; Wang P; Zhou H; An J
    Virol Sin; 2019 Jun; 34(3):243-252. PubMed ID: 30911897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
    Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
    Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serological diagnostic test systems assessing the immune response to Japanese encephalitis vaccination.
    Litzba N; Klade CS; Lederer S; Niedrig M
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e883. PubMed ID: 21103412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an assay for detection of Japanese encephalitis virus specific antibody responses.
    Pushpakumara PD; Jeewandara C; Gomes L; Perera Y; Wijewickrama A; Malavige GN; Goonesekara C
    PLoS One; 2020; 15(10):e0238609. PubMed ID: 33112881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
    Bonaparte M; Dweik B; Feroldi E; Meric C; Bouckenooghe A; Hildreth S; Hu B; Yoksan S; Boaz M
    BMC Infect Dis; 2014 Mar; 14():156. PubMed ID: 24656175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cross-reactivity between flaviviruses with sera of patients with Japanese encephalitis showed the importance of neutralization tests for the diagnosis of Japanese encephalitis.
    Maeki T; Tajima S; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Lim CK; Saijo M
    J Infect Chemother; 2019 Oct; 25(10):786-790. PubMed ID: 31105002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological evidence of DENV, JEV, and ZIKV among the indigenous people (Orang Asli) of Peninsular Malaysia.
    Khor CS; Mohd-Rahim NF; Hassan H; Tan KK; Zainal N; Teoh BT; Sam SS; Khoo JJ; Lee HY; Lim YA; Abubakar S
    J Med Virol; 2020 Aug; 92(8):956-962. PubMed ID: 31814135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody rather than cellular immune response is maintained for nearly 20 years among Japanese encephalitis SA14-14-2 vaccinees in an endemic setting.
    Wang R; Fan D; Wang L; Li Y; Zhou H; Gao N; An J
    Infect Genet Evol; 2020 Nov; 85():104476. PubMed ID: 32736041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme.
    Sudjaritruk T; Kaewpoowat Q; Prasarakee C; Sarachai S; Taurel AF; Sricharoen N; Assawawongprom P; Saheng J; Harris R; Nealon J; Yoksan S
    PLoS Negl Trop Dis; 2022 Aug; 16(8):e0010674. PubMed ID: 35913983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.